Jump to content

Lysergic acid 2,4-dimethylazetidide

From Wikipedia, the free encyclopedia
(Redirected from LSZ)
"LSZ" redirects here. For other uses, see LSZ (disambiguation).
Lysergic acid 2,4-dimethylazetidide
Clinical data
Other namesLysergic acid 2,4-dimethylazetidine, Diazedine, Lambda, LSZ
Routes of
administration		Oral
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • Illegal in Denmark, France,[1] Sweden and Switzerland
Identifiers
  • [(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]-[(2S,4S)-2,4-dimethylazetidin-1-yl]methanone
​
  • freebase: (S,S)-isomer, freebase
  • tartrate salt: (S,S)-isomer, tartrate salt
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC21H25N3O
Molar mass335.451 g·mol−1
3D model (JSmol)
  • freebase: C[C@H]1C[C@@H](N1C(=O)[C@H]2CN([C@@H]3CC4=CNC5=CC=CC(=C45)C3=C2)C)C
  • freebase: InChI=1S/C21H25N3O/c1-12-7-13(2)24(12)21(25)15-8-17-16-5-4-6-18-20(16)14(10-22-18)9-19(17)23(3)11-15/h4-6,8,10,12-13,15,19,22H,7,9,11H2,1-3H3/t12-,13-,15+,19+/m0/s1 ☒N
  • Key:DUKNIHFTDAXJON-CTQRGLTFSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ) is an analog of LSD developed by the team led by David E. Nichols at Purdue University.[2][3] It was developed as a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor. There are three possible stereoisomers around the azetidine ring, with the (S,S)-(+) isomer being the most active, slightly more potent than LSD itself in drug discrimination tests using trained rats.[4]

There have been several unconfirmed reports of lysergic acid 2,4-dimethylazetidide being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as "diazedine" and "λ".[5][6]

Dosage and effects

[edit]

The dosage of LSZ in humans is said to be 100 to 300 μg orally, which is higher than the listed dosage of LSD (60–200 μg).[7][8] According to David E. Nichols, LSZ is about equipotent with LSD in humans.[9] Hence, unlike in rodents, LSZ does not appear to be more potent than LSD in humans.[7]

Pharmacology

[edit]
LSZ activities
Target Affinity (Ki, nM)
5-HT1A 0.45
5-HT1B 2.4
5-HT1D 2.4
5-HT1E 276
5-HT1F ND
5-HT2A 0.54–19.2 (Ki)
0.32–957 (EC50Tooltip half-maximal effective concentration)
56–85% (EmaxTooltip maximal efficacy)
5-HT2B 27 (Ki)
0.4–58.4 (EC50)
57–74% (Emax)
5-HT2C 37 (Ki)
992 (EC50)
39% (Emax)
5-HT3 >10,000
5-HT4 ND
5-HT5A 27.3
5-HT6 14.5
5-HT7 14.3
α1A 850.2
α1B >10,000
α1D–α2C ND
β1 75.8
β2 1,069
β3 ND
D1 292
D2 73.6–110
D3 6.0
D4 36–95.5
D5 402.2
H1 2,504
H2–H4 ND
M1–M5 ND
I1 ND
σ1, σ2 ND
TAAR1Tooltip Trace amine-associated receptor 1 ND
SERTTooltip Serotonin transporter >10,000 (Ki)
NETTooltip Norepinephrine transporter >10,000 (Ki)
DATTooltip Dopamine transporter >10,000 (Ki)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [10][11][12][4][13][14][15][16][17]

LSZ produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.[7] It shows about the same potency as LSD in producing this effect.[7] However, LSZ shows a weaker maximal HTR than LSD or AL-LAD in terms of magnitude.[2] The drug also substitutes for LSD in rodent drug discrimination tests.[7][4] It was about 1.8-fold more potent than LSD in this assay.[7][4]

History

[edit]

In 2013, LSZ also appeared on some designer drug and research chemical markets in the United Kingdom.[18] LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012.[19]

Society and culture

[edit]
[edit]

United Kingdom

[edit]

On June 10, 2014, the United Kingdom Advisory Council on the Misuse of Drugs (ACMD) recommended that LSZ be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use.[18] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.

Switzerland

[edit]

LSZ is illegal in Switzerland as of December 2015,[20] in Denmark as of May 2015,[21] and in Sweden as of January 26, 2016.[22]

See also

[edit]

References

[edit]
  1. ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". www.legifrance.gouv.fr (in French). 20 May 2021.
  2. ^ a b Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 9 (1): 38–50. doi:10.1002/dta.1985. PMC 5411264. PMID 27265891.
  3. ^ Schifano F, Orsolini L, Papanti D, Corkery J (June 2016). "NPS: Medical Consequences Associated with Their Intake". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. Springer International Publishing. pp. 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. OCLC 643052237. PMID 27272067.
  4. ^ a b c d Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (September 2002). "Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)". J Med Chem. 45 (19): 4344–4349. doi:10.1021/jm020153s. PMID 12213075.
  5. ^ Morris H (1 May 2011). "Life Is a Cosmic Giggle on the Breath of the Universe". Vice Magazine. Retrieved 2011-06-15.
  6. ^ Cole K (2005). Lysergic. Indianapolis: Dog Ear Publishing. ISBN 978-1598580075.
  7. ^ a b c d e f Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species" (PDF). Neuropharmacology. 167: 107933. doi:10.1016/j.neuropharm.2019.107933. PMC 9191653. PMID 31917152. Table 4 Human potency data for selected hallucinogens. [...]
  8. ^ Mallaroni P, Mason NL, Vinckenbosch FR, Ramaekers JG (June 2022). "The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides". Psychopharmacology (Berl). 239 (6): 1783–1796. doi:10.1007/s00213-022-06142-4. PMC 9166850. PMID 35487983.
  9. ^ Nichols DE (October 2018). "Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)" (PDF). ACS Chemical Neuroscience. 9 (10): 2331–2343. doi:10.1021/acschemneuro.8b00043. PMID 29461039.
  10. ^ "Kᵢ Database". PDSP. 1 April 2025. Retrieved 1 April 2025.
  11. ^ Liu, Tiqing. "BindingDB BDBM50118576 (2,4-Dimethyl-azetidin-1-yl)-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-methanone::CHEMBL137781". BindingDB. Retrieved 1 April 2025.
  12. ^ Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
  13. ^ Braden MR (2007). Towards a biophysical understanding of hallucinogen action (Ph.D. thesis). Purdue University. ProQuest 304838368.
  14. ^ McCorvy JD (16 January 2013). "Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics". Purdue e-Pubs. Archived from the original on 26 March 2025.
  15. ^ Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL (January 2017). "Crystal Structure of an LSD-Bound Human Serotonin Receptor". Cell. 168 (3): 377–389.e12. doi:10.1016/j.cell.2016.12.033. PMC 5289311. PMID 28129538.
  16. ^ Nichols DE (2012). "Structure–activity relationships of serotonin 5-HT2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi:10.1002/wmts.42. ISSN 2190-460X.
  17. ^ Nichols DE (2018). Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43. doi:10.1007/7854_2017_475. ISBN 978-3-662-55878-2. PMID 28401524.
  18. ^ a b ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.
  19. ^ Power M (2014-01-29). "The Drug Revolution That No One Can Stop".
  20. ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.
  21. ^ "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Lægemiddelstyrelsen. 31 August 2015.
  22. ^ "31 nya ämnen kan klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. November 2015.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lysergic_acid_2,4-dimethylazetidide&oldid=1283426122"